Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28257184 | 0.88 | CA2 (0.53) | NAPRTTSHRTDP1CA2MAPT | |
| Pyridine SCHEMBL2424842 | 0.88 | CA2 (0.53) | NAPRTTSHRTDP1CA2MAPT | |
| Pyridine SCHEMBL28040883 | 0.86 | CA2 (0.50) | NAPRTTSHRTDP1CA2 | |
| Pyridine SCHEMBL8570319 | 0.84 | NAPRT (0.43) | NAPRTTSHRTDP1CA2 | |
| Pyridine SCHEMBL5606559 | 0.84 | NAPRT (0.43) | NAPRTTSHRTDP1CA2 | |
| Pyridine SCHEMBL6671998 | 0.80 | NAPRT (0.39) | NAPRTTSHRTDP1CA2 | |
| Pyridine SCHEMBL9785253 | 0.78 | NAPRT (0.47) | NAPRTTSHRTDP1CA2MAPT | |
| Pyridine SCHEMBL2255454 | 0.78 | NAPRT (0.47) | NAPRTTSHRTDP1CA2MAPT | |
| Pyridine SCHEMBL984983 | 0.78 | TSHR (0.53) | NAPRTTSHRTDP1 | |
| Pyridine SCHEMBL407438 | 0.77 | NAPRT (0.60) | NAPRTTSHRTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294748-A | A kind of synthetic method for Ge Lieting key intermediate | 浙江沙星科技有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-109803952-A | Sulfamic acid derivatives and preparation method thereof | 魁北克电力公司 | 2019-05-24 | — | — | CN | claimed |
| CN-108349938-A | Salts of Pim Kinase Inhibitors | 因赛特公司 | 2018-07-31 | — | — | CN | claimed |
| CN-107501359-A | A kind of Fondaparinux sodium impurity compound and preparation method and application | 深圳市海滨制药有限公司 | 2017-12-22 | — | — | CN | claimed |
| EP-1304338-B1 | Process for the preparation of Chondroitin sulfates from K4 Polysaccharide and obtained products | IBSA INST BIOCHIMIQUE SA (CH) | 2008-08-13 | — | — | EP | claimed |
| US-20030100534-A1 | Process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products | IBSA INSTITUT BIOCHIMIQUE S.A. (CH) | 2003-05-29 | — | — | US | claimed |
| EP-1304338-A1 | Process for the preparation of Chondroitin sulfates from K4 Polysaccharide and obtained products | Ibsa Institut Biochimique S.A. (CH) | 2003-04-23 | — | — | EP | claimed |
| CN-110218213-A | The thick cyclics of pyrans, preparation method and use | 北京天一绿甫医药科技有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-106029057-B | Oral formulations of pyrrolidine derivatives | 奥布赛瓦股份公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-110121499-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-109928905-A | As oxytocins/pitressin V1a receptor antagonist pyrrolidin derivatives | 奥布赛瓦股份公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-109937206-A | Polymerizable compound, and method for producing borane phosphate oligomer | 学校法人东京理科大学 | 2019-06-25 | — | — | CN | disclosed |
| CN-109879979-A | A kind of antioxidant and preparation method thereof | 武汉轻工大学 | 2019-06-14 | — | — | CN | disclosed |
| US-20030060448-A1 | Use of hyaluronic acid derivatives in the preparation of biomaterials with a physical haemostatic and plugging activity and a preventive activity in the formation of adhesions following anastomosis | ANIKA THERAPEUTICS S.R.L. (IT) | 2003-03-27 | — | — | US | disclosed |
| EP-0971961-B1 | N-SULPHATED HYALURONIC ACID COMPOUNDS, DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION | FIDIA ADVANCED BIOPOLYMERS SRL (IT) | 2002-12-04 | — | — | EP | disclosed |
| US-20020037874-A1 | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation | FIDIA ADVANCED BIOPOLYMERS | 2002-03-28 | — | — | US | disclosed |
| EP-0999859-A2 | USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS | FIDIA ADVANCED BIOPOLYMERS S.R.L. (IT) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999004828-A2 | USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS | FIDIA ADVANCED BIOPOLYMERS, S.R.L. (IT) | 1999-02-04 | — | — | WO | disclosed |
| EP-0439555-A1 | NOVEL DERMATAN SULFATE AND HEPARIN OLIGOSACCHARIDES HAVING ANTIATHEROSCLEROTIC ACTIVITY. | OPOCRIN SPA (IT) | 1991-08-07 | — | — | EP | disclosed |
| WO-1990004607-A2 | NOVEL DERMATAN SULFATE AND HEPARIN OLIGOSACCHARIDES HAVING ANTIATHEROSCLEROTIC ACTIVITY | OPOCRIN S.P.A. LABORATORIO FARMACOBIOLOGICO (IT) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100534-A1 | Process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products | CSGALNACT1, DDOST, STT3B | NAPRT 803/4885TSHR 4098/4885TDP1 4431/4885 |
| US-20020037874-A1 | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation | HPSE, CD44, HEXD | NAPRT 110/4885TSHR 3434/4885TDP1 4196/4885 |
| US-20030060448-A1 | Use of hyaluronic acid derivatives in the preparation of biomaterials with a physical haemostatic and plugging activity and a preventive activity in the formation of adhesions following anastomosis | MMP1, PLG, CD44 | NAPRT 2185/4885TSHR 4025/4885TDP1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.